Explore

Turn Therapeutics Publishes Study on GX-03's Efficacy in Inflammatory Skin Disease Model

Turn Therapeutics Publishes Study on GX-03's Efficacy in Inflammatory Skin Disease Model

Turn Therapeutics Publishes Study on GX-03's Efficacy in Inflammatory Skin Disease Model

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

Brenus Pharma, a biotechnology company specializing in immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for STC-1010. This drug is designed to treat microsatellite stable (MSS) metastatic colorectal cancer (mCRC), a condition affecting approximately 95% of mCRC patients who typically show minimal response to standard immunotherapies. The FDA's approval allows Brenus Pharma to proceed with clinical evaluations in the U.S. under the BreAK-CRC001 study. This development follows European regulatory approvals and initial positive results from early Phase Ia trials. The company plans to present further data at the ESMO annual congress in 2026.

Oligonucleotide Manufacturers Shift to Cost-Effective High Production Methods Amid Rising Demand

Oligonucleotide Manufacturers Shift to Cost-Effective High Production Methods Amid Rising Demand

Oligonucleotide Manufacturers Shift to Cost-Effective High Production Methods Amid Rising Demand

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

D Pharmatech Reports Positive Results for Zabopegdutide in MASH Treatment

D Pharmatech Reports Positive Results for Zabopegdutide in MASH Treatment

D Pharmatech Reports Positive Results for Zabopegdutide in MASH Treatment

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

PharmaEssentia to Present Clinical Data on Ropeginterferon Alfa-2b for Essential Thrombocythemia at ASCO and EHA 2026

PharmaEssentia to Present Clinical Data on Ropeginterferon Alfa-2b for Essential Thrombocythemia at ASCO and EHA 2026

PharmaEssentia to Present Clinical Data on Ropeginterferon Alfa-2b for Essential Thrombocythemia at ASCO and EHA 2026

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment